SPOTLIGHT -
EP. 1: Classifying Indolent Versus Active Myeloma
EP. 2: Treating High-Risk Asymptomatic Myeloma
EP. 3: New Data for Newly Diagnosed Myeloma
EP. 4: Which Proteasome Inhibitor for Upfront Treatment of Myeloma?
EP. 5: Transplant in Multiple Myeloma
EP. 6: Consolidation/Maintenance Therapy in Myeloma
EP. 7: Elderly Patients With Myeloma
EP. 8: Relapsed/Refractory Myeloma: Daratumumab-Containing Triplets
EP. 9: Choosing Triplet Therapy at Myeloma Relapse
EP. 10: Emerging Therapies for Myeloma
EP. 11: Immunotherapy for Myeloma & Final Thoughts on Myeloma Research at ASH 2016
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
